德國和法國漢堡/ACCESSWIRE/2022年7月6日/Evotec SE(法蘭克福證券交易所股票代碼：EVT，MDAX/TecDAX，ISIN：DE0005664809；納斯達克：EVO)，領先的研究驅動型生物製藥公司勃林格-英格爾海姆公司，以及世界領先的體外培養診斷公司今天宣佈，他們已經成立了一家合資企業，以創造下一代抗菌素以及可操作的診斷藥物，以對抗抗菌素耐藥性(AMR)。
熱門資訊> 正文
Evotec、Boehringer Inelheim和BioMérieux推出Aurobac，一家抗擊抗菌素耐藥性的合資企業
2022-07-06 13:55
HAMBURG, GERMANY and FRANCE / ACCESSWIRE / July 6, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).
The resulting company, Aurobac Therapeutics SAS, will combine the best-of-best capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to cure. The aspiration is to succeed in the fight against AMR, which is a major public health threat. Having routine surgery such as caesarean sections or hip replacements may become life threatening, and complications from common diseases such as diabetes and injuries or cuts will become harder to manage because of AMR.
合併后的公司Aurobac Treateutics SAS將結合三家創始公司的最佳能力，開發從診斷到治癒的新的精準醫學方法。他們的願望是在抗擊AMR的鬥爭中取得成功，AMR是一個主要的公共健康威脅。進行剖腹產或髖關節置換等常規手術可能會危及生命，糖尿病和損傷或割傷等常見疾病的併發症將因為AMR而變得更難處理。
Werner Lanthaler, CEO of Evotec, said: "The grim prospect of a post-antibiotic era has many causes but only one solution: The development of new, targeted, and effective antimicrobial therapies. We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMérieux, to combine our complementary strengths. By leveraging Evotec's multimodality approach to infectious diseases, we are confident that Aurobac will be able to generate much-needed progress to tackle the global challenge of AMR".
Evotec首席執行官維爾納·蘭塔勒表示：后抗生素時代的嚴峻前景有很多原因，但解決方案只有一個：開發新的、有針對性的和有效的抗菌療法。我們很高興與我們在勃林格-英格爾海姆和BioMérieux的合作伙伴一起推出Aurobac，將我們的互補優勢結合在一起。通過利用Evotec對傳染病的多模式方法，我們相信Aurobac將能夠取得亟需的進展，以應對AMR的全球挑戰「。
"The rise of antibiotic-resistant infections - also called antimicrobial resistance, or AMR - is indeed a looming global crisis," added Michel Pairet, Head of Boehringer Ingelheim's Innovation unit and Member of the Board of Managing Directors. "Antibiotic resistance kills about 1.27 million people globally every year 1 and it has been estimated that by 2050, as many as 10 million worldwide deaths could result from AMR 2 , making it potentially deadlier than cancer."
「抗藥性感染(也稱為抗菌素耐藥性，簡稱AMR)的上升確實是一場迫在眉睫的全球危機。」勃林格-英格爾海姆創新部門負責人兼董事會成員米歇爾·佩雷特補充道。每年全球約有127萬人死於抗生素耐藥性 1據估計，到2050年，全球可能有多達1000萬人死於AMR 2，使其潛在地比癌症更致命。
"bioMérieux has a strong expertise in antimicrobial resistance. We supply the most comprehensive integrated diagnostic solutions to support an appropriate use of antibiotics (antimicrobial stewardship)", said Alexandre Mérieux, bioMérieux Chairman and CEO. "Our role within the joint venture is to develop and commercialize diagnostic tests, including Companion Diagnostics, which deliver rapid, reliable and actionable results. This participation in Aurobac is perfectly aligned with bioMérieux' full commitment to sustain antibiotic efficacy for future generations".
Bio Mérieux在抗菌素耐藥性方面擁有強大的專業知識。我們提供最全面的綜合診斷解決方案，以支持抗生素的適當使用(抗菌素管理)。BioMérieux董事長兼首席執行官亞歷山大·梅里尤説。我們在合資企業中的角色是開發診斷測試並將其商業化，包括Companion Diagnostics，它可以提供快速、可靠和可操作的結果。參與Aurobac與BioMérieux為子孫后代保持抗生素療效的全面承諾完美地結合在一起。
Aurobac will work to shift the strategy related to antibiotic treatment regimens, which at the moment leans heavily on empirical approaches using broad-spectrum and unfocused medicines. The goal is to turn this into a precision approach, using new highly effective and targeted modalities, combined with rapid and actionable diagnostics to quickly identify pathogens and their resistance patterns, and supported by new economic models.
Aurobac將努力改變與抗生素治療方案相關的戰略，目前該方案嚴重依賴於使用廣譜和非重點藥物的經驗方法。目標是將其轉變為一種精確的方法，使用新的高效和有針對性的模式，結合快速和可操作的診斷來快速識別病原體及其耐藥模式，並得到新的經濟模型的支持。
Funded by Boehringer Ingelheim as lead investor with € 30 m and by Evotec and bioMérieux with € 5 m each, the € 40 m joint venture, which has its headquarters in Lyon (France), combines the world leading expertise of Evotec, one of the most active research companies in infectious diseases, with bioMérieux's market-leading expertise in infectious disease diagnostics and with Boehringer Ingelheim's broad drug discovery and significant clinical development capabilities.
該合資公司總部設在法國里昂，由勃林格-英格爾海姆作為主投資者，出資3000萬歐元，由Evotec和BioMérieux各出資500萬歐元，投資4000萬歐元，將傳染病領域最活躍的研究公司之一Evotec的世界領先專業知識與BioMérieux在傳染病診斷方面的市場領先專業知識以及勃林格-英格爾海姆廣泛的藥物發現和重要的臨牀開發能力相結合。
Three partners committed to combat AMR
Evotec has built a world-leading platform to tackle infectious diseases. With a more than 200-strong anti-infective discovery team, the company has proven experience on multiple agent classes. On top of the company's own pre-competitive pandemic preparedness and rapid response technology platform ("PRROTECT"), Evotec leverages its infectious disease capabilities with many industry, academic and non-profit partners and is active in a variety of networks such as the AMR Accelerator that is part of the EU's Innovative Medicines Initiative ("IMI").
三個合作伙伴致力於抗擊AMR
Evotec已經建立了一個世界領先的應對傳染病的平臺。該公司擁有200多名抗感染藥物發現團隊，在多種藥物類別上擁有成熟的經驗。除了該公司自己的賽前流行病預防和快速反應技術平臺(「PRROTECT」)之外，Evotec還利用其與許多行業、學術和非營利性合作伙伴的傳染病能力，並活躍在各種網絡中，例如作為歐盟創新葯物倡議(「IMI」)的一部分的AMR加速器。
Boehringer Ingelheim's participation in Aurobac is part of a wider so-called pandemic preparedness initiative, which includes a € 50 m investment in the AMR action fund by Boehringer Ingelheim. Boehringer Ingelheim Venture Fund has committed to invest up to € 12 m in AMR infection companies.
勃林格-英格爾海姆對Aurobac的參與是一項更廣泛的所謂大流行防備計劃的一部分，該計劃包括勃林格-英格爾海姆向AMR行動基金投資5000萬歐元。勃林格-英格爾海姆風險基金已承諾向AMR感染公司投資1200萬歐元。
bioMérieux has over 55 years of diagnostics expertise with more than 75% of its research and development budget focused on antimicrobial resistance. Moreover, 80% of its turnover is related to the fight against AMR through a complete diagnostic solution facilitating antibiotic therapy decision-making, including antibiotic initiation, optimization, and discontinuation.
Biomérieux擁有超過55年的診斷專業知識，其75%以上的研發預算專注於抗菌素耐藥性。此外，該公司80%的營業額與通過促進抗生素治療決策的完整診斷解決方案對抗AMR有關，包括抗生素的啟動、優化和停用。
1
2
1
2
ABOUT BOEHRINGER INGELHEIM
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at
關於勃林格·英格爾海姆
伯林格·英格爾海姆正在致力於突破性的療法，以改變今天和未來幾代人的生活。作為一家領先的研究驅動型生物製藥公司，該公司通過在高度未得到滿足的醫療需求領域的創新創造價值。成立於1885年，此后一直為家族所有的勃林格-英格爾海姆公司着眼於長遠。超過52,000名員工服務於人類製藥、動物健康和生物製藥代工這三個業務領域的130多個市場。瞭解更多信息
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2021, revenues reached €3.4 billion, with over 90% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
關於Biomérieux
先鋒診斷學
自1963年以來，BioMérieux一直是體外診斷領域的世界領先者，業務遍及44個國家和地區，在大型分銷商網絡的支持下為160多個國家和地區提供服務。2021年，收入達到34億歐元，其中90%以上的銷售額來自法國以外。Biomérieux提供診斷解決方案(系統、試劑、軟件和服務)，以確定疾病和污染源，以改善患者健康並確保消費者安全。其產品主要用於診斷傳染病。它們還用於檢測農業食品、藥品和化粧品中的微生物。
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM - ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
Biomérieux在巴黎泛歐交易所上市。
符號：BIM-ISIN代碼：FR0013280286
路透社：BIOX.PA/彭博社：BIM.FP
ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,200 highly qualified people. The Company's 16 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to and follow us on Twitter @Evotec and LinkedIn .
關於Evotec SE
Evotec是一家生命科學公司，擁有獨特的商業模式，實現了發現和開發高效療法並將其提供給患者的使命。該公司的多模式平臺包括創新技術、數據和科學的獨特組合，用於發現、開發和生產一流和一流的製藥產品。Evotec利用這種「數據驅動的研發Autobahn to Cures」進行專有項目和合作夥伴網絡的治療，合作伙伴網絡包括所有排名前20的製藥公司和800多家生物技術公司、學術機構以及其他醫療保健利益相關者。Evotec在目前服務不足的廣泛治療領域開展戰略活動，包括神經學、腫瘤學以及新陳代謝和傳染病。在這些專業領域內，Evotec致力於創建世界領先的共同擁有的創新療法管道，迄今已建立了從早期發現到臨牀開發的200多個專有和共同擁有的研發項目組合。Evotec在全球擁有超過4200名高素質的員工。該公司的16個站點提供高度協同的技術和服務，並作為互補的卓越集羣運營。欲瞭解更多信息，請訪問 並在推特上關注我們@Evotec和LinkedIn.
FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
前瞻性陳述
本公告包含有關未來事件的前瞻性陳述，包括擬發行和上市的研華證券。諸如「預期」、「相信」、「可能」、「估計」、「期望」、「打算」、「可能」、「可能」、「計劃」、「潛在」、「應該」、「目標」、「將會」等詞語以及此類詞語和類似表述的變體旨在識別前瞻性陳述。這些陳述包括有關研華對收入、集團EBITDA和非合作研發費用的預期的評論。這些前瞻性陳述是基於研華作出這些陳述時所掌握的信息，以及研華認為合理的預期和假設。不能保證這樣的預期將被證明是正確的。這些陳述涉及已知和未知的風險，並基於一些假設和估計，這些假設和估計本身就會受到重大不確定性和意外情況的影響，其中許多超出了研發科的控制範圍。研華科技明確表示不承擔任何義務或承諾公開發布對本文中包含的任何前瞻性陳述的任何更新或修訂，以反映研華科技對此的預期的任何變化，或任何陳述所基於的事件、條件或情況的任何變化。
Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com
媒體聯繫人Evotec SE：
全球企業傳播和營銷高級副總裁加布里埃爾·漢森電話：+49.(0)40.56081-255電子郵件：gabriele.hansen@evotec.com
IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com
IR聯繫Evotec SE：
全球投資者關係和ESG高級副總裁Volker Braun電話：+49.(0)40.56081-775電子郵件：volker.braun@evotec.com
SOURCE: Evotec SE
資料來源：Evotec SE
View source version on accesswire.com:
在accesswire.com上查看源代碼版本：
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
